October 5, 2017

The New Frontier of Autoimmune and Autoinflammatory Diseases

What is cancer immunotherapy teaching us?

17-RHE-1216 Calabrese Hero Image 650x450pxl

By Leonard Calabrese, DO

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

It has been the dream of oncologists to develop a safe, targeted, host-sparing form of cancer immunotherapy since the nineteenth century, when Dr. William Coley pioneered one of the earliest iterations of cancer immunotherapy by injecting bacteria directly into tumors. Over the past 140 years, numerous attempts to refine cancer immunotherapy have led to a string of disappointments from simple lack of efficacy to dramatic toxicities.

In 2011, the first of a new class of agents known as checkpoint inhibitors was approved for the treatment of advanced melanoma, beginning a new era in cancer immunotherapy. Following the approval of ipilimumab, five other monoclonal antibodies have been approved, and many more are in development. A quick scan of clinictrials.gov reveal over 1300 active clinical trials in the cancer immunotherapy arena.

Why this matters for rheumatologists

Checkpoint inhibitors derive their name from critical nodes of control located throughout the integrated immune system. Consider that a naïve T cell, once it encounters its cognate antigen (such as an infection or vaccine), can activate and proliferate several log phases and ultimately grow to over a million progeny in seven to 10 days. Implicit with such activation and proliferation is the capacity to down regulate, whereby a small number become memory cells and the majority die in programmed cell death pathways. These negative controls are often referred to as checkpoints and include CTLA4 (expressed on CD4 and CD8 cells, as well as PD1). While these molecules are the focus of current inhibitors, researchers are examining many other candidates including TIM-3, LAG-2, CD160, VISTA and others.

T-cell activation is highly choreographed, requiring two signals for activation (i.e. TCR and Antigen & CD28 and CD80/86). Following activation, proliferation and differentiation check points such as CTLA4-CD80/86 and PD1-PDL1 or PDL2 intervene and brake the system. Figure republished with permission from BMJ Publishing Group Ltd.

Advertisement

Drugs targeting these checkpoints reinvigorate T cells in the tumors, leading to apoptosis and hopefully remission from advancing cancers. To date, these therapies have been highly effective in some tumors used both singly and in combination.

By now most rheumatologists as well as other specialists are aware that checkpoint inhibitors are capable of unleashing a wide array of autoimmune and autoinflammatory adverse events found virtually within every organ system. These complications have posed new challenges to all practitioners, and guidelines for the management of some but not all have been proposed.

The next frontier

Recent work has suggested that these same checkpoints may have a role to play in the pathogenesis of de novo autoimmunity as well. Work from the University of Cambridge has demonstrated that the same type of exhausted T cells that is bad for cancer may be good for autoimmunity, correlating with higher rates of remission and milder disease. It remains to be seen whether these important translational observations can be converted into therapy or biomarkers useful for patients with autoimmune diseases.

The pathogenesis of these immune-related adverse events or irAEs will be discussed at the 6th Annual Basic and Clinical Immunology for the Busy Clinician to be held March 9-10, 2018, in Miami Beach, Florida. This one-of-a-kind course features three distinct modules: Fundamentals of Basic and Clinical Immunology, Immune Therapeutics (Advances in Biology Therapies for IMIDs), and Immunologic Health. It will also include daily yoga and mindfulness meditation.

To view the full agenda and faculty and to register, visit www.ccfcme.org/clinical.

Advertisement

This activity has been approved for AMA PRA Category 1 Credit™.

Dr. Calabrese is Director of the R.J. Fasenmyer Center for Clinical Immunology.

Related Articles

Medical illustration of hand with discolored fingers
February 27, 2024
Coexistence of Erythromelalgia and Raynaud’s Phenomenon

Treatment strategies require understanding of pathomechanisms

Squamous cell skin cancer
November 30, 2023
Skin Cancer Risk in Immunosuppressed Patients

Education, prevention strategies and monitoring serves this at-risk group

esophageal plaques
November 28, 2023
Esophageal Plaques and Systemic Sclerosis

Treatment for scleroderma can sometimes cause esophageal symptoms

Lupus clinic
November 24, 2023
Coordinated Care, Education and Research

Lupus Clinic providers collaborate to advance treatment and understanding

Skin lesions
November 15, 2023
Case Study: Joint Pain, Angioedema, Confusing Rash

Symptoms complement one another

Sjogren's Syndrome medical illustration
July 25, 2023
Case: Getting to the Root of Neuropathic Symptoms

Collaboration was key to identifying source of nerve condition

Middle-aged Black woman talks with doctor
July 21, 2023
Emerging Treatments for Systemic Lupus Erythematosus

A review of expanding options that hold new promise

20-RHE-2006260-Langford_VEXAS-syndrome-CQD-650×450 play
May 3, 2023
Case Study: Making the VEXAS Diagnosis (Video)

Patient’s symptoms included periorbital edema, fevers, weight loss

Ad